Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
Hai Feng,Yunhui Zhuo,Xuemei Zhang,Yuyao Li,Yue Li,Xiangjuan Duan,Jia Shi,Chengbin Xu,Yueqiu Gao,Zhuo Yu
DOI: https://doi.org/10.2147/JHC.S381764
2022-10-27
Journal of Hepatocellular Carcinoma
Abstract:Hai Feng, 1, &ast Yunhui Zhuo, 2, &ast Xuemei Zhang, 2 Yuyao Li, 1 Yue Li, 1 Xiangjuan Duan, 2 Jia Shi, 1 Chengbin Xu, 3 Yueqiu Gao, 1, 2 Zhuo Yu 2 1 Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 3 Department of Informatics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yueqiu Gao, Institute of Infectious Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China, Tel +86 21 20256507, Fax +86 21 20256699, Email Zhuo Yu, Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China, Tel +86 21 20256507, Fax +86 21 20256699, Email Hepatocellular carcinoma (HCC) remains a serious medical therapeutic challenge as conventional curative avenues such as surgery and chemotherapy only benefit for few patients with limited tumor burden. Immunotherapy achieves clinical progress in the treatment of this prevalent malignant disease by virtue of the development of tumor immunology; however, most patients have experienced minimal or no clinical benefit in terms of overall survival. The complexity and diversity of tumor microenvironment (TME) built by immune and stromal cell subsets has been considered to be responsible for the insufficiency of immunotherapy. The advance of bioanalytical technology boosts the exploration of the composition and differentiation of these infiltrated cells, which reflect the immune state of the TME and impact the efficacy of the antitumor immune response. Targeting these cells to remodel the TME is one of the important immunotherapeutic approaches to improve HCC treatment. In this review, we focused on the role of these non-cancerous cells in the tumor progression, and elaborated their function on cancer immunotherapy when manipulating them as potential targets. Keywords: immune cells, stromal cells, tumor microenvironment, hepatocellular carcinoma, immunotherapy Hepatocellular carcinoma (HCC) is a serious prevalent malignancy, and therapeutic options rely on tumor burden and the severity of concurrent liver disease. The early-stage loco-regional tumors are primarily treated with the modalities such as surgery, radiofrequency ablation (RFA), and transarterial embolization (TAE), but high post-operative recurrence usually caused the dreadful prognosis. 1–3 Multikinase inhibitors, representatives as sorafenib, lenvatinib, and regorafenib, have been approved as systemic chemotherapeutic agents in the treatment of advanced-stage unresectable tumors. 4,5 However, higher rate of severe drug-related adverse events results in the interruption of the treatment, thus injuring the efficacy and long-term outcomes of patients. 6 In addition, the intolerance of patients with compromised liver failure to the toxicities also impedes the procurement of maximal benefit from these drugs. 7,8 Some improved strategies like metronomic capecitabine administration at low dose without break, and dose modification of regorafenib based on monitoring real-time outcome have been assessed in clinical trials, and the effect is striking but still needs to be confirmed. 9,10 To improve therapeutic efficacy and life quality of patients, novel approaches different from the abovementioned mechanisms are urgently required. Recent advances in studying the connection between chronic inflammation and oncogenesis, and the phenomenon of immune infiltrate in neoplastic tissue indicates that immunotherapy is an appealing strategy to reduce HCC proliferation, invasion and metastasis. 11 The discovery of T cell-suppressive immune checkpoints including CTLA-4, PD-1, and its ligand PD-L1 illuminates the prospect of cancer immunotherapy. Many antibody-based immune checkpoint inhibitors (ICIs) including ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), pembrolizumab (anti-PD-1), durvalumab (anti-PD-L1), atezolizumab (anti-PD-L1), etc. have been developed for the treatment of HCC patients, and the effects of these agents were being evaluated in clinical practice. 12–14 Despite these ICIs exhibiting the efficacy in the preliminary use, accumulating evidences in multiple clinical trials indicated the disappointing results for them us -Abstract Truncated-
oncology